Tuberculosis treatment and drug regimens

Area of Science:

• Microbiology
• Infectious Diseases
• Public Health

Background:

• Tuberculosis (TB) is an airborne infectious disease requiring combination therapy.
• Patient adherence to long-term antituberculosis therapy is critical for maintaining therapeutic drug levels.
• Inadequate medical management contributes to the emergence and spread of drug-resistant Mycobacterium tuberculosis strains.

Purpose of the Study:

• To highlight the challenges in managing drug-resistant tuberculosis.
• To discuss the limitations of current and novel therapeutic options.
• To emphasize the need for new research and public health strategies.

Main Methods:

• Literature review of current tuberculosis treatment guidelines and drug resistance patterns.
• Analysis of the impact of drug resistance on treatment efficacy and patient outcomes.
• Examination of the role of new antituberculosis drugs (bedaquiline, delamanid) in clinical management.

Main Results:

• Drug-resistant tuberculosis presents complex treatment challenges due to limited, toxic, and expensive alternatives.
• Newly approved drugs like bedaquiline and delamanid are not definitive solutions, especially in high-resistance settings.
• Intermediate economy countries face significant hurdles in managing drug-resistant tuberculosis.

Conclusions:

• Continued research and development of novel antituberculosis agents are urgently required.
• Effective public health policies are essential to preserve existing and future therapeutic options.
• Integrated strategies are needed to combat the growing threat of drug-resistant tuberculosis globally.